Reading
Reading
Reading, Pennsylvania, United States40 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-10-06 | NCT03191149 | |
| Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-10-05 | NCT01863550 | |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | B-cell chronic lymphocytic leukemia, Chronic Disease, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male Urogenital Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, acute myeloid leukemia, adenocarcinoma, benign urinary system neoplasm, bone marrow disorder, breast disorder, breast neoplasm, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal disorder, gastric neoplasm, gastroesophageal junction adenocarcinoma, head and neck carcinoma, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, intestinal disorder, invasive breast carcinoma, kidney cancer, kidney disorder, leukemia, lung disorder, lung neoplasm, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, myeloid leukemia, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal disorder, renal carcinoma, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, skin neoplasm, stomach disorder, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Not stated | 2026-10-02 | NCT05334069 | |
| Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, adenosquamous lung carcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT04929041 | |
| Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT02595944 | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Adnexal Diseases, Blood Protein Disorders, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast carcinoma, breast disorder, breast neoplasm, carcinoma, carcinoma of esophagus, cardiovascular disorder, cervical carcinoma, cervix disorder, colon carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, esophageal disorder, exocrine pancreatic carcinoma, female reproductive system disorder, female reproductive system neoplasm, gastric carcinoma, gastric neoplasm, glioma, gonadal disorder, head and neck carcinoma, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, hepatocellular carcinoma, immune system disorder, immunoproliferative disorder, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung carcinoma, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, monoclonal gammopathy, neoplasm, neuroendocrine neoplasm, neuroepithelial neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, pancreas disorder, pancreatic neoplasm, plasma cell neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate carcinoma, prostate disorder, rectal carcinoma, rectal disorder, rectal neoplasm, renal carcinoma, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin carcinoma, skin disorder, skin neoplasm, stomach disorder, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, urinary bladder carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine cancer, uterine disorder, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-10-01 | NCT02465060 | |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not applicable | 2026-10-01 | NCT02194738 | |
| Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT02115282 | |
| Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, breast carcinoma in situ, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01272037 | |
| Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00843882 | |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, lymphoid interstitial pneumonia, mouth disorder, neoplasm, salivary gland cancer, salivary gland disorder, salivary gland squamous cell carcinoma, squamous cell carcinoma, tongue cancer, tongue carcinoma, tongue disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00588770 | |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | breast adenocarcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00433511 | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00310180 | |
| St. Joseph's HPV Self-sampling: Offering a Self-sampling Option in Clinic | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Not applicable | 2026-09-18 | NCT05092022 | |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | invasive breast carcinoma | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04266249 | |
| Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery | Stage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7 | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-14 | NCT03070886 | |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-08-19 | NCT05774951 | |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-08-19 | NCT04566328 | |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) | Charcot-Marie-Tooth disease type 1F, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Active, not recruiting | Phase 3 | 2026-08-18 | NCT05147220 | |
| Assessment of CCM in HF With Higher Ejection Fraction | cardiovascular disorder, diastolic heart failure, heart disorder, heart failure | Recruiting | Not applicable | 2026-08-06 | NCT05064709 | |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma | Recruiting | Phase 3 | 2026-08-05 | NCT05812807 | |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung large cell carcinoma, lung neoplasm, minimally invasive lung adenocarcinoma, neoplasm, respiratory tract neoplasm, squamous cell lung carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-04 | NCT01386385 | |
| Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2026-07-27 | NCT04877691 | |
| Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung cancer, lung disorder, lung neoplasm, minimally invasive lung adenocarcinoma, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not stated | 2026-07-16 | NCT00499330 | |
| Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-07-14 | NCT02032823 |